Lilly beyond the AI trade
Tim Seymour saw a rotation into healthcare. Nancy Tengler said she had added Lilly while looking beyond technology. Their dated views give us a specific company to investigate if leadership broadens.
October 26–30, 2026 · close to close
The October 26–30 move includes Lilly’s October 29 earnings release. It does not establish that rotation caused the gain.
Get Idea Scout free
Investor ideas, disagreements and changes of mind, with dates and sources. One email every Sunday.
Free · double opt-in · unsubscribe in one click
The dated views behind the Lilly story
Seymour discussed healthcare rotation on October 20; Tengler discussed looking beyond tech on October 26. Both disclosed Lilly exposure. These are statement dates, not purchase prices or execution dates.
LLY · Tim Seymour (Seymour Asset Management)
Seymour said he was long Lilly and Novo Nordisk while arguing that healthcare looked attractive as a rotation trade.
LLY · Nancy Tengler (Laffer Tengler Investments)
Asked whether she was looking beyond tech, Tengler said yes and said she had added Eli Lilly after a long spell of underperformance.
Editorial summaries of public statements. Dates belong to the cited sources; they are not trade execution dates.
Our read & what could change it
Lilly is worth researching as a source of growth beyond concentrated AI-stock exposure. The operating results give that case substance; investor agreement alone does not establish an attractive valuation.
We are watching whether demand and the oral-drug rollout can sustain growth as realized prices fall. Slower volume growth or a worsening price mix would weaken the case.
What the earnings added
On October 29, Lilly reported 39% revenue growth, with volume up 53% and realized prices down 15%. The company raised its full-year revenue outlook. Lilly’s original October 29 release ↗
Price calculation: $1,279.14 on October 26, 2026 to $1,417.54 on October 30, 2026. c8alpha daily-price record; close to close, without dividends. This is a stock-price observation, not a portfolio return.
Research reviewed November 3, 2026. Planned review: November 17, 2026, including any evidence against the case.
Explore the public LLY record
Who said what, and what LLY did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
Who’s talking about LLY
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-10-27 | Eddie GhabourCo-founder & CEO, Key Advisors Wealth Management | Bullish | Fox Business (uncut) | Eli Lilly should continue benefiting from its GLP-1 leadership, successful AI monetization, international… |
| 2026-10-26 | Nancy TenglerCEO & CIO, Laffer Tengler Investments | Bullish | Fox Business (uncut) | Added Eli Lilly after a prolonged underperformance spell and continues to hold as a name worth owning on dips |
| 2026-10-26 | Jeff Meechum | Bullish | CNBC (uncut) | Medicare GLP-1 access starting July 1 provides a 3Q tailwind, with further upside from global oral GLP-1… |
| 2026-10-26 | Jim Cramer (CNBC)Host, CNBC's Mad Money | Bullish | CNBC (uncut) | Eli Lilly has a credible path to $2T market cap from $1.2T, endorsed by deep-industry insiders as the top… |
| 2026-10-20 | Tim Seymour (Seymour Asset Mgmt)CIO, Seymour Asset Management | Bullish | CNBC (uncut) | Eli Lilly and Novo Nordisk offer similar obesity-drug fundamentals despite Novo receiving disproportionately… |
| 2026-10-15 | Todd GordonCo-founder & Director of Investments, Inside Edge Capital | Bullish | CNBC (uncut) | Eli Lilly's new oral GLP-1 pill offers superior dosing convenience (any time) versus Novo Nordisk's… |
| 2026-10-14 | Jared HolzManaging Director and Healthcare Equity Strategist, Mizuho | Bullish | CNBC (uncut) | Eli Lilly has the strongest 5-year outlook in large-cap pharma due to its GLP-1 franchise accomplishments and… |
| 2026-08-18 | Joe Terranova (Virtus)Chief market strategist, Virtus | Bullish | CNBC Halftime Final Trades | Eli Lilly's price action is technically positioned to break out to a new all-time high imminently, offering a… |
| 2026-08-04 | Unknown Investment Committee | Bullish | CNBC Halftime Final Trades | Eli Lilly's valuation has compressed from above 50x to the low 30s, yet the company is still expected to… |
| 2026-06-05 | Scott GallowayNYU Stern professor & podcast host | Bullish | Prof G Pod (Galloway) | GLP-1 drugs like Zepbound work nearly universally, address obesity as a 'nodal health condition' linked to… |
Show all 12 mentions
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-06-04 | Scott GallowayNYU Stern professor & podcast host | Bullish | Prof G Pod (Galloway) | Eli Lilly is the closest thing to a pure-play index fund on GLP-1 technology, which Galloway believes is more… |
| 2025-01-18 | David MandelbaumPortfolio Manager, OnePoint BFG | Bullish | Wealthion | Eli Lilly has been beaten down by temporary supply and inventory headwinds, but the obesity drug addressable… |
Public mention history has a seven-day lag. The dated example above is a selection from that record.
Last reports
| Report | When | EPS actual vs est. | Reaction |
|---|---|---|---|
| 29 Oct 2026 | before the open | 7.48 vs 6.32 | +5.4% |